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Novel function of ceramide for regulation of mitochondrial
ATP release in astrocytes
Ji-Na Kong,1,*,† Zhihui Zhu,1,*,§ Yutaka Itokazu,* Guanghu Wang,*,§ Michael B. Dinkins,*
Liansheng Zhong,*,§,** Hsuan-Pei Lin,*,§ Ahmed Elsherbini,*,§ Silvia Leanhart,* Xue Jiang,§,††
Haiyan Qin,§ Wenbo Zhi,§§ Stefka D. Spassieva,2,§ and Erhard Bieberich2,*,§
Department of Neuroscience and Regenerative Medicine* and Center of Biotechnology and Genomic
Medicine,§§ Medical College of Georgia, Augusta University, Augusta, GA; Department of Biology,†
Massachusetts Institute of Technology, Cambridge, MA; Department of Physiology,§ University of Kentucky,
Lexington, KY; College of Basic Medicine,** China Medical University, Shenyang, People’s Republic of
China; and Rehabilitation Center,†† ShengJing Hospital of China Medical University, Shenyang, People’s
Republic of China

Abstract We reported that amyloid  peptide (A42) activated neutral SMase 2 (nSMase2), thereby increasing the
concentration of the sphingolipid ceramide in astrocytes.
Here, we show that A42 induced mitochondrial fragmentation in wild-type astrocytes, but not in nSMase2-deficient cells
or astrocytes treated with fumonisin B1 (FB1), an inhibitor
of ceramide synthases. Unexpectedly, ceramide depletion
was concurrent with rapid movements of mitochondria, indicating an unknown function of ceramide for mitochondria.
Using immunocytochemistry and super-resolution microscopy, we detected ceramide-enriched and mitochondriaassociated membranes (CEMAMs) that were codistributed
with microtubules. Interaction of ceramide with tubulin
was confirmed by cross-linking to N-[9-(3-pent-4-ynyl-3-Hdiazirine-3-yl)-nonanoyl]-D-erythro-sphingosine (pacFACer),
a bifunctional ceramide analog, and binding of tubulin to
ceramide-linked agarose beads. Ceramide-associated tubulin
(CAT) translocated from the perinuclear region to peripheral CEMAMs and mitochondria, which was prevented in
nSMase2-deficient or FB1-treated astrocytes. Proximity ligation and coimmunoprecipitation assays showed that ceramide depletion reduced association of tubulin with
voltage-dependent anion channel 1 (VDAC1), an interaction
known to block mitochondrial ADP/ATP transport. Ceramidedepleted astrocytes contained higher levels of ATP, suggesting that ceramide-induced CAT formation leads to
VDAC1 closure, thereby reducing mitochondrial ATP release, and potentially motility and resistance to A42. Our
data also indicate that inhibiting ceramide generation may
protect mitochondria in Alzheimer’s disease.—Kong, J-N.,
Z. Zhu, Y. Itokazu, G. Wang, M. B. Dinkins, L. Zhong, H-P. Lin,
A. Elsherbini, S. Leanhart, X. Jiang, H. Qin, W. Zhi, S. D.
Spassieva, and E. Bieberich. Novel function of ceramide for
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regulation of mitochondrial ATP release in astrocytes.
J. Lipid Res. 2018. 59: 488–506.
Supplementary key words adenosine 5′-triphosphate • sphingolipids •
mitochondria-associated membranes

In addition to accumulating amyloid  peptide (A42), elevation of ceramide and mitochondrial damage is observed
in Alzheimer’s disease (AD) (1, 2). Our laboratory discovered that incubation of astrocytes with A42 activates neutral
SMase 2 (nSMase2), a bona fide signaling enzyme generating
ceramide from sphingomyelin (3, 4). While examining the
effect of A42 on astrocytes in time-lapse imaging, we discovered that mitochondria in nSMase2-deficient astrocytes were
more resistant to A42-induced damage, but they also moved
more rapidly than those in wild-type astrocytes. nSMase2 has
been shown to shuttle between the plasma membrane and
Golgi and it is activated by mitochondrial lipids (5–8),
prompting us to test the effect of nSMase2-generated ceramide on mitochondrial motility and function.
Ceramide is a sphingolipid the concentration of which is
less than 1 mol% (compared with approximately 10 mol%

Abbreviations: ACN, acetonitrile; AD, Alzheimer’s disease; A42,
amyloid  peptide; CAT, ceramide-associated tubulin; CEC, ceramideenriched compartment; CerS, ceramide synthase; CEMAM, ceramideenriched and mitochondria-associated membrane; dSTORM, direct
stochastic optical reconstruction microscopy; ER, endoplasmic reticulum; FB1, fumonisin B1; MAM, mitochondria-associated membrane;
nSMase2, neutral SMase 2; NSTORM, Nikon STORM OMM, outer mitochondrial membrane; pacFACer, N-[9-(3-pent-4-ynyl-3-H-diazirin-3-yl)nonanoyl]-D-erythro-sphingosine; PLA, proximity ligation assay; SigmaR1,
sigma 1 receptor; STORM, stochastic optical reconstruction micro
scopy;VDAC1, voltage-dependent anion channel 1.
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sphingomyelin) in cellular membranes (9). It is mainly synthesized in the endoplasmic reticulum (ER) by ceramide
synthases (CerSs), which attach a variety of fatty acid residues to long chain bases, such as sphingosine and dihydrosphingosine, or by hydrolysis of sphingomyelin that is
catalyzed by different SMases in distinct cellular compartments, such as the plasma membrane, lysosomes, the
Golgi apparatus, and mitochondria (10–15). Increase of
ceramide levels through upregulation of CerSs or SMases
leads to induction of apoptosis and other cell signaling
pathways critical for cell death, senescence, autophagy, or
cell cycle arrest. We and others showed that the localized
generation or distribution of ceramide in ceramide microdomains (rafts) or more extended ceramide-enriched
compartments (CECs) may have additional cellular functions of ceramide (16–23). Instrumental to our studies was
the generation of a ceramide-specific antibody originally
developed in our laboratory (24). This antibody has been
shared with several independent laboratories to reliably detect and visualize ceramide in cells and tissues and it is the
only antibody applicable to super-resolution microscopy
using stochastic optical reconstruction microscopy (STORM)
(3, 18, 25–27). In addition to the ceramide-specific antibody, we developed a novel imaging protocol based on
cross-linking of photoactivatable ceramide analogs {bifunctional ceramide or N-[9-(3-pent-4-ynyl-3-H-diazirine-3-yl)nonanoyl]-D-erythro-sphingosine (pacFACer)} that can be
derivatized with fluorophores or biotin using click chemistry. We demonstrated that these ceramide analogs are distributed to CECs and can be used to visualize and identify
proteins binding to ceramide (19).
Previous studies showed that ceramide analogs were
cross-linked or bound to tubulin (28, 29). We showed that
tubulin was coimmunoprecipitated when pulling down
intracellular vesicles using anti-ceramide IgG (20). These
studies suggested that ceramide may bind to free tubulin
dispersed in the cytosol, or to tubulin embedded into microtubules or associated with cellular membranes (membrane tubulin). Membrane tubulin has been detected in
the plasma membrane, but also in other compartments
and organelles, such as the ER and mitochondria (30, 31).
Tubulin has been suggested to bind to lipids in the cytosolic leaflet of the outer mitochondrial membrane (OMM)
to initiate closure of voltage-dependent anion channel 1
(VDAC1) (32–34), one of the key channels mediating ADP/
ATP transport between mitochondria and the cytosol.
Malfunction of mitochondria and dysregulated VDAC1
have been implicated in many neurodegenerative diseases,
including AD, Huntington’s disease, Parkinson’s disease,
amyotrophic lateral sclerosis, and frontotemporal dementia (35–42). In AD, A has been shown to bind to VDAC1,
reduce ATP levels, and cause mitochondrial fragmentation during early stages of the disease (35, 43, 44). VDAC1
downregulation has been reported to reduce cellular ATP
levels and induce mitochondrial fragmentation (45, 46),
eventually leading to neurodegeneration. In astrocytes,
VDAC1 is critical for secretion of ATP, a gliotransmitter
regulating synaptic plasticity and neuronal function (47–50).
Most recently, VDAC1 closure by tubulin has been suggested

to be critical for the Warburg effect, a metabolic switch
from mitochondria-mediated oxidative phosphorylation to
glycolysis for ATP production, often observed in cancer
cells (51–53).
While assays with mitochondria showed that lipid-tubulin interaction is important for tubulin-mediated VDAC1
closure (52, 54–56), the role of ceramide in this regulation
has not been investigated yet. In addition, there is only little information available on the role of lipid-tubulin interaction for the function of mitochondria in intact cells.
Studies from several laboratories found that ceramide is
enriched in mitochondria and mitochondria-associated
membranes (MAMs) (57, 58). MAMs are a subcompartment of the ER that forms contact sites with mitochondria
and takes part in the cross-talk between mitochondria and
microtubules. While CerSs and nSMases have been shown
to generate ceramide in mitochondria involved in inducing apoptosis (59–62), it is not known whether ceramide
regulates the function of MAMs and whether this involves ceramide-associated tubulin (CAT) and its effect on
VDAC1.
To test a potential role of CAT located at MAMs for the
regulation of mitochondria, we used several complementary experimental approaches: 1) determining the effect
of ceramide depletion by nSMase2 deficiency or the CerS
inhibitor, fumonisin B1 (FB1), on mitochondrial morphology and motility; 2) confocal microscopy and STORM
using anti-ceramide IgG for testing the association of ceramide with mitochondria and microtubules; 3) cross-linking of pacFACer and binding to ceramide agarose beads to
test ceramide association to tubulin; 4) proximity ligation
assays (PLAs) and coimmunoprecipitation assays to quantify CAT and CAT-VDAC1 complexes in primary cultured
astrocytes and test the effect of ceramide depletion on
complex formation; and 5) measurement of ATP levels in
nSMase2-deficient or FB1-treated astrocytes to determine
the effect of ceramide depletion on CAT-induced VDAC1
closure. Our results suggest that CAT localized at ceramide-enriched MAMs (CEMAMs) induces interaction of
tubulin with VDAC1, a novel regulatory mechanism critical for mitochondria and, potentially, pathophysiology in
AD.

MATERIALS AND METHODS
Reagents
MitoTracker Red CM-H2Xros (M-7513), Duolink PLA probe
anti-rabbit plus (DUO92002), Duolink PLA probe anti-mouse
minus (DUO92004), Duolink PLA probe anti-goat minus
(DUO92006), Duolink detection reagent red (DUO92008), Duolink detection reagent green (DUO92014), Alexa Fluor 647 azide
(A10277), Invitrogen Click-iT cell reaction buffer kit (C10269),
and Click-iT protein reaction buffer kit (C10276) were purchased
from Thermo Fisher Scientific (West Columbia, SC); CytoPainter
mitochondrial staining kit-green fluorescence (ab112143) and
ATP photometric/fluorimetric assay (ab83355) were from Abcam
(Cambridge, MA); pacFACer was obtained from Avanti Polar Lipids
(Alabaster, AL); TAMRA-azide-desthiobiotin (1110-5) was from
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Click Chemistry Tools (Scottsdale, AZ); cyanine 7.5 azide (A6030)
was purchased from Lumiprobe (Hallandale Beach, FL); 2-mercaptoethanol (636890), cysteamine (30070), glucose oxidase from
Aspergillus niger type VII (G2133-250 KU), and catalase from bovine
liver (C40) were purchased from Sigma-Aldrich (St. Louis, MO).
A1-42 was from Anaspec (Freemont, CA) dissolved in 1% ammonia and diluted to 1 mg/ml and neutralized in PBS prior to use.

Preparation and treatment of primary astrocytes cultures
All experiments were carried out according to an Animal Use
Protocol approved by the Institutional Animal Care and Use Committee at Augusta University and the University of Kentucky. Primary glial cells were isolated from brains of P0-P1 (day at birth or
next day) C57BL/6 wild-type or nSMase2-deficient fro/fro mouse
pups. Brains were dissociated in PBS containing 0.1 M glucose,
passed through a 40 m filter, and plated in T-25 flasks in DMEM
(Life Technologies, Grand Island, NY) supplemented with 10%
fetal bovine serum, and 1% penicillin/streptomycin solution at
37°C in a humidified atmosphere containing 5% CO2. After 7
days, adherent cells were passed to 24-well plates containing uncoated glass coverslips and cultured in DMEM as described above.

Immunocytochemistry and confocal microscopy
Cells were fixed with 4% p-formaldehyde/0.5% glutaraldehyde/PBS for 15 min and then permeabilized by incubation with
0.2% Triton X-100 in PBS for 5 min at room temperature. Nonspecific binding sites were blocked with 3% ovalbumin/PBS for
1 h at 37°C. The primary antibodies used were: anti-acetylated tubulin mouse IgG (1:3,000, Sigma-Aldrich, clone 6-1113-1, T6793),
anti-ceramide rabbit IgG (1:100, our laboratory) (20, 24), anticeramide mouse IgM (1:100, MAB0014, Glycobiotech GmbH),
anti-sigma receptor 1 goat IgG (1:200, Santa Cruz, clone S-18,
sc-22948), anti--tubulin mouse monoclonal IgG (1:200, Santa
Cruz, clone B-7, sc-5286), anti--tubulin goat IgG (1:200, Santa
Cruz, clone N-20, sc-9935), anti--tubulin mouse monoclonal
IgG (1:200, Santa Cruz, clone D-10, sc-5274), anti-calnexin goat
IgG (1:200, Santa Cruz, sc-6465), anti-Tom 20 rabbit IgG (1:200,
Santa Cruz, sc-11415), anti-tubb4 mouse IgG (1:200, Invitrogen,
1-20247), anti-IP3 receptor mouse IgG (1:200, University of California Davis/National Institutes of Health NeuroMab facility,
clone L2418), anti-VDAC1 rabbit IgG (1:500, Abcam, ab15895).
Secondary antibodies (Alexa Fluor 546-conjugated donkey antirabbit IgG, Cy5-conjugated donkey anti-mouse IgM -chain specific, Alexa Fluor 647-conjugated goat anti-mouse IgG -chain
specific (all Jackson ImmunoResearch, West Grove, PA) were diluted 1:300 in 0.1% ovalbumin/PBS and samples incubated for
2 h at 37°C. After washing, coverslips were mounted using Fluoroshield supplemented with DAPI (Sigma-Aldrich) to visualize the
nuclei. Confocal fluorescence microscopy was performed using a
Zeiss LSM780 upright confocal laser scanning microscope (Zeiss,
Jena, Germany) equipped with a two-photon argon laser at 488,
543, or 633 nm. Images were processed using Zeiss Zen software.

Image analysis of colocalization and motility
Randomly chosen sections of images (blinded) were analyzed
using the colocalization 2 function in Fiji/Image J software. The
degree of colocalization was assessed by calculation of the Pearson’s
correlation coefficient for two fluorescence channels in overlays,
as previously described (63). A similar technique was used for determining motility of mitochondria using overlays of two consecutive time frames assigned to two different fluorescence channels.
Motility was inversely correlated to the Pearson’s correlation coefficient in the overlay. All of the data were collected from three
independent cell cultures using five randomly selected areas per
culture for determination of mitochondrial motility.
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NSTORM
Cells were fixed and subjected to immunocytochemistry using
primary antibodies, as described for confocal microscopy. To ensure the optical properties required for STORM, Atto 488 antirabbit and Alexa Fluor 647 anti-mouse antibodies were used as
secondary antibodies. Samples were immersed in buffers prepared as follows: buffer A, 10 mM Tris (pH 8.0) + 50 mM NaCl;
buffer B, 50 mM Tris (pH 8.0) + 10 mM NaCl + 10% glucose;
GLOX solution (250 l), 14 mg glucose oxidase (Sigma-Aldrich)
+ 50 l catalase from bovine liver-lyophilized powder (17 mg/ml)
(Sigma-Aldrich) + 200 l buffer A. Buffers A and B were freshly
prepared, vortexed, and spun down at 13,000 rpm. Only the supernatant was used for preparing the NSTORM imaging buffer
by adding 7 l GLOX and 70 l 1 M cysteamine (MEA) (SigmaAldrich) to 620 l buffer B in a 1.5 ml Eppendorf tube on ice,
followed by gently mixing and adding the buffer to the sample for
imaging. NSTORM was performed using a Nikon Storm microscope equipped with 405, 488, 561, and 633 nm lasers and proprietary software for image reconstruction.

Cross-linking to pacFACer and click chemistry-mediated
tagging with fluorophores
Astrocytes were incubated under protection from light for 5–60
min in DMEM medium with vehicle (1:1,000 ethanol/2% dodecane) or 5 M of the bifunctional ceramide analog, pacFACer
(Avanti Polar Lipids) diluted 1:1,000 from a stock in ethanol/2%
dodecane. Cells were UV irradiated at 365 nm for 15 min at room
temperature and fixed with 4% p-formaldehyde/0.5% glutaraldehyde/PBS for 15 min. Unbound pacFACer was removed by washing
and fixing with ice-cold methanol for 15 min. For immunocytochemistry, cells were washed with PBS, equilibrated with click reaction buffer, and the click reaction performed using the Click-iT
cell reaction buffer kit using Alexa Fluor 594-azide or TAMRAazide-biotin as fluorophores following the manufacturer’s protocol (Life Technologies).

pacFACer cross-linking and streptavidin pull-down
Homogenates of primary cultured astrocytes were incubated
with pacFACer (10 M) for 30 min at room temperature. The
homogenate was UV irradiated at 365 nm for 20 min. Unbound
pacFACer was removed by chloroform/methanol precipitation.
Protein precipitates were dissolved with 1% SDS in 50 mM TrisHCl buffer (pH 7.5) and sonicated. The click reaction was performed using the Click-iT protein reaction buffer kit (Thermo
Fisher Scientific) with 500 M of biotin azide (Sigma-Aldrich)
following the manufacture’s protocol. Unbound biotin azide
was removed by chloroform/methanol precipitation. The resulting protein pellets were dissolved in 1% SDS in 50 mM
Tris-HCl buffer (pH 7.5), diluted to 0.1% SDS for pull-down
experiment. The insoluble materials were removed by centrifugation at 20,000 g for 5 min at room temperature. Supernatants
equivalent to the same amount of protein were incubated with
25 l of preequilibrated NeutrAvidin beads (Thermo Fisher
Scientific) for 2 h at room temperature. Beads were washed
10 times with 0.1% SDS in 50 mM Tris-HCl buffer (pH 7.5). For
immunobloting, pacFAcer-binding proteins were eluted with
SDS-sample buffer containing 10% 2-mercaptoethanol for
30 min at 60°C.

Affinity purification using ceramide beads
Ceramide-coated beads (P-BCer, Echelon Bioscience) and control beads (P-B000, Echelon Bioscience) were incubated with an
equal amount of astrocyte lysates. In detail, primary cultured astrocytes were harvested in ceramide binding buffer [20 mM TrisHCl, 150 mM NaCl, and 1 mM EDTA (pH 7.5) supplemented
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with protein inhibitor cocktail (Roche)]. The cells were homogenized by glass homogenizer on ice, and complete lysis of cells was
achieved by sonication. After insoluble debris was removed by
centrifugation at 20,800 g for 30 min at 4°C, Triton X-100 was
added to the supernatant at 0.25% of final concentration. A 20 l
slurry of ceramide beads and control beads was added to the supernatant and incubated at 4°C overnight under rotary agitation.
Beads were harvested by centrifugation at 4°C, 500 g for 5 min and
washed four times with ceramide binding buffer supplemented
with 0.25% Triton X-100. The bound proteins were eluted by SDSsample buffer containing 10% 2-mercaptoethanol for 30 min at
60°C and then subjected to SDS-PAGE either for immunoblotting
or Coomassie staining. Stained bands were cut out and subjected
to proteomics analysis.

pacFACer ELISA and cross-linking to recombinant tubulin
Binding assays were performed using pacFACer lipid ELISA
as described previously (19, 20, 24). Briefly, pacFACer (500 ng
in 100 l ethanol) was coated on 96-well Immulon-1B ELISA
plates (Thermo Fisher Scientific/Life Technologies) and washed
with PBS. Nonspecific binding sites were blocked by incubation for 1 h at 37°C with 100 l of 1% BSA in PBS. Tubulin
purified from pig brain (80 ng/l, T240-T240-A; Cytoskeleton, Denver, CO) in PBS was incubated for 1 h at 37°C. Wells
were UV irradiated at 365 nm for 15 min at room temperature.
Unbound tubulin was removed by washing four times with PBS
and then the click reaction performed using the Click-iT cell
reaction buffer kit with Cy7.5-azide as fluorophore following
the manufacturer’s protocol (Life Technologies). Click chemistry reagent was removed and the wells were washed four
times with PBS. SDS sample buffer was added into the wells to
collect protein samples.

Protein identification
Gel bands were excised from SDS-PAGE gels, cut into 1 mm
pieces, destained using 50% acetonitrile (ACN) in 25 mM ammonium bicarbonate, dried, reduced with dithiothreitol, alkylated using iodoacetamide, and digested overnight using trypsin. Peptides
were extracted using 5% formic acid in 50% ACN and were dried.
Peptide digests were analyzed on an Orbitrap Fusion Tribrid mass
spectrometer (Thermo Fisher Scientific) coupled with an Ultimate
3000 nano-UPLC system (Thermo Fisher Scientific). Two microliters of reconstituted peptide were first trapped and washed on a
Pepmap100 C18 trap (5 m, 0.3 × 5 mm) at 20 l/min using 2%
ACN in water (with 0.1% formic acid) for 10 min and then separated
on a Pepman 100 RSLC C18 column (2.0 m, 75 m × 150 mm)
using a gradient of 2–40% ACN with 0.1% formic acid over 40 min
at a flow rate of 300 nl/min and a column temperature of 40°C.
Samples were analyzed by data-dependent acquisition in positive mode using an Orbitrap MS analyzer for precursor scan at
120,000 FWHM from m/z 300 to 1,500 and ion-trap MS analyzer
for MS/MS scans at top speed mode (3 s cycle time). Collisioninduced dissociation was used as fragmentation method. Raw data
were processed using Proteome Discoverer (v1.4; Thermo Fisher
Scientific) and submitted for SequestHT search against the UniProt database pertinent to the origin of the sample. Fixed value
PSM validator algorithm was used for peptide spectrum matching
validation. SequestHT search parameters were 10 ppm precursor
and 0.6 Da product ion tolerance, with static carbamidomethylation (+57.021 Da).

PLAs and quantitative analysis
Astrocytes were grown on glass coverslips. Cells were fixed with
4% p-formaldehyde/0.5% glutaraldehyde/PBS for 15 min at
37°C and then permeabilized by incubation with 0.2% Triton

X-100 in PBS for 5 min at room temperature. Nonspecific binding
sites were blocked with Duolink PLA blocking solution (SigmaAldrich) for 1 h at 37°C. The primary antibodies used were: anticeramide rabbit IgG (1:100, our laboratory) (20, 24), anti-VDAC1,
and anti-tubb 4/5. Secondary PLA probes, anti-rabbit PLUS affinitypurified donkey anti-rabbit IgG (H+L), anti-goat MINUS affinitypurified donkey anti-goat IgG (H+L), and anti-mouse MINUS
affinity-purified donkey anti-mouse IgG (H+L), were diluted 1:5
in 1× antibody diluent buffer and samples incubated for 1 h at
37°C. After washing, ligation and amplification steps were performed following the manufacturer’s protocol (Sigma-Aldrich).
Coverslips were mounted using Fluoroshield supplemented with
DAPI (Sigma-Aldrich) to visualize the nuclei. Zeiss LSM780 upright confocal microscopy was performed as described in one of
the previous sections. Zen software was used for initial image acquisition and dots counted using ImageJ. Images obtained with
secondary antibody only were used as negative controls representing the background intensity in a particular laser channel.

Isolation of mitochondria and coimmunoprecipitation assay
HEK293T cells were seeded on the 100 mm dishes with 35–
40% of density, in the absence or presence of 3 M FB1 (11635583-0; Cayman, Ann Arbor, MI). Sixty hours later, the untreated
cells and the treated cells were harvested and washed twice with
ice-cold PBS. The cell pellets were transferred into a Dounce homogenizer and lysed with 2 ml of ice-cold mitochondria extraction buffer [125 mM sucrose, 250 mM mannitol, 10 mM HEPES,
10 mM EGTA, 0.01% BSA, and protease inhibitors (pH 7.2)]. To
enrich for mitochondria, the homogenate was transferred into a
centrifuge tube and cell debris pelleted at 700 g, 4°C for 10 min.
The supernatant was centrifuged once again under the same
conditions and subsequently, transferred to a new ice-cold tube
followed by centrifugation at 10,000 g for 15 min at 4°C. The mitochondrial pellet was resuspended in 1 ml of lipid binding buffer
[20 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA (pH 7.5), and 1%
digitonin, supplemented with protein inhibitor cocktail (Roche)]
and complete lysis of mitochondrial membranes was achieved by
sonication. Insoluble debris was removed by centrifugation at
10,000 g for 15 min at 4°C. The protein concentration in the supernatants from untreated cells and treated cells was adjusted to
the same concentration and the same volume. Lysates were precleared with Pierce protein A/G magnetic beads (88802; Pierce
Biotechnology, Rockford, IL) and then incubated overnight with
nonspecific mouse IgG (control) or anti -tubulin mouse IgG at
4°C under rotational movement. The next morning, 15 l of
Pierce protein A/G magnetic beads were added to the samples
and incubated for 2 h at room temperature under rotational
movement. The beads were harvested and washed three times by
lipid binding buffer without digitonin. Protein bound to the
beads was eluted by SDS-sample buffer containing 10% 2-mercaptoethanol for 30 min at room temperature. The protein preparation was subjected to SDS-PAGE for immunoblotting using
anti-VDAC1 rabbit IgG.

ATP determination
Wild-type and fro/fro astrocytes (106 cells) were detached using
trypsin/EDTA solution and resuspended in ice-cold PBS. Total
cellular ATP was determined following the fluorescence protocol
as described in the manual provided by the supplier (Abcam). All
measurements were performed in triplicate and normalized to
cell number and protein.

Morphometric analysis of mitochondria
Measurement of mitochondrial length (L) and width (W), perimeter (P), and area (A) was achieved using ImageJ after correction
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for contrast and background. Mitochondrial morphology was analyzed using standard protocols for quantitation of mitochondrial
length (L), aspect ratio (L/W), and form factor (P2/4A), as previously described (64).

Statistical analysis
The mean, SEM, and statistical tests of control and treatment
samples were calculated using GraphPad Prism. Student’s t-test
was used to compare two groups, one-way ANOVA with Bonferroni post hoc test for three or more groups. Values of at least P <
0.05 were considered significant.

Miscellaneous
For immunoblot analysis, protein concentrations were determined using the RC/DC protein assay, in accordance with the
manufacturer’s (Bio-Rad) instructions. Equal amounts of protein
were loaded onto a 4–20% gradient gel, and SDS-PAGE was
performed using the Laemmli method. For immunoblotting,
membranes were first blocked with 5% dry milk in PBST (PBS
containing 0.1% Tween-20) and incubated with primary antibodies in the blocking buffer overnight at 4°C. Membranes were
then washed three times with PBS/0.05% Tween and incubated
with the appropriate horseradish peroxidase-conjugated secondary antibodies for 1 h at room temperature. After washing,
bands were detected using an Odyssey imaging system from
Licor or Pico and Femto ECL assay from Pierce/Thermo Fisher
Scientific.

RESULTS
Mitochondria in ceramide-depleted astrocytes are
resistant to A-induced fragmentation and show
increased motility
Our previous studies showed that incubation with A42
leads to increased levels of ceramide in primary cultured
astrocytes and that nSMase2 deficiency reduces ceramide
levels and sensitivity of astrocytes to A-induced apoptosis
(supplemental Fig. S1A) (4). In addition, it has been shown
that A42 induces fragmentation of mitochondria (44).
Therefore, we tested to determine whether mitochondria
in nSMase2-deficient astrocytes were resistant to A-induced
fragmentation. Figure 1A shows that overnight exposure to
1 M A42 led to fragmented mitochondria in wild-type,
but not in nSMase2-deficient, astrocytes (see supplemental
Fig. S1B, C for controls). Fragmentation led to about 50%
reduction in mitochondrial length, aspect ratio, and form
factor (Fig. 1B–D), consistent with previous studies showing similar effects of amyloid on mitochondrial morphology (64). As an alternative approach to deplete cells of
ceramide, we used the CerS inhibitor, FB1, which also protected astrocytes from mitochondrial fragmentation (supplemental Fig. S1A, ceramide profile; supplemental Fig.
S1D, E, mitochondria). These results suggested that independent of the affected metabolic pathway (via nSMase2
or CerS-mediated de novo biosynthesis), ceramide depletion was protective for mitochondria in astrocytes.
When evaluating time-lapse images of mitochondria labeled with MitoTracker or CytoPaint, we noticed that numerous mitochondria in nSMase2-deficient or FB1-treated
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astrocytes were rapidly moving, while those in wild-type
cells were predominantly resting (supplemental Movies,
supplemental Fig. S2A–C). Increase of mitochondrial motility by ceramide depletion was unexpected and has not
been described before. Motility was quantified by determining colocalization of individual mitochondria in consecutive time frames of time-lapse images and comparing
wild-type with nSMase2-deficient astrocytes. Mitochondria
at the cell periphery of nSMase2-deficient astrocytes showed
about 30% higher motility than those in wild-type cells,
while mitochondria close to the nucleus were almost immotile (Fig. 1E, F). These results indicated an unknown
function of ceramide in the regulation of mitochondrial
distribution or motility.
Ceramide is enriched in mitochondrial-associated
membranes and codistributes with microtubules and
tubulin
To begin testing the role of ceramide in mitochondria,
we visualized the distribution of ceramide within cellular
compartments important for mitochondrial motility using
a rabbit polyclonal anti-ceramide antibody originally developed in our laboratory (24). Figure 2A, B shows that the
ceramide label codistributed with sigma 1 receptor (SigmaR1), a marker for MAMs, and MitoTracker, a marker
for mitochondria. In nSMase2-deficient or FB1-treated
wild-type cells, codistribution of ceramide label with MAMs
and mitochondria was significantly reduced (Fig. 2B; supplemental Fig. S2D, E), indicating that ceramide generated by both nSMase2 and CerS is critical for ceramide
enrichment in a subpopulation of MAMs, particularly in
the cell periphery (arrows in Fig. 2B). We refer to this
compartment as ceramide-enriched MAMs or CEMAMs.
Because peripheral mitochondria in ceramide-depleted
cells showed higher motility, we tested to determine whether
ceramide depletion would alter the distribution of CEMAMs
along microtubules. Figure 2C shows that codistribution
of the ceramide label with acetylated tubulin was significantly reduced in nSMase2-deficient astrocytes. The morphological appearance of ceramide-labeled vesicular and
tubular structures along microtubules (arrows in Fig. 2C,
left panel) in wild-type cells prompted us to analyze the
codistribution of ceramide with microtubules at higher
resolution. Figure 3A, B shows that ceramide was colabeled
with microtubules and appeared to form contact structures
that were also detected by super-resolution fluorescence
microscopy (NSTORM, arrows in Fig. 3B, C). Codistribution of ceramide with acetylated tubulin was also detected
in astrocytes in tissue sections of mouse brain, confirming
the results obtained with cell cultures (supplemental Fig.
S3A). The results obtained with anti-ceramide rabbit IgG
were confirmed using anti-ceramide mouse IgM, another
antibody reported to detect ceramide using immunocytochemistry (supplemental Fig. S3B) (24, 65). Despite partial
overlap, the distribution of ceramide and acetylated tubulin was not identical, consistent with the assumption that
ceramide is primarily enriched in CEMAMs associated
with microtubules as well as mitochondria. Figure 3D shows
that ceramide was codistributed with mitochondria and

Supplemental Material can be found at:
http://www.jlr.org/content/suppl/2018/01/10/jlr.M081877.DC1
.html

Fig. 1. Ceramide depletion increases resistance to A and mitochondrial motility. A: Wild-type and nSMase2-deficient astrocytes were incubated overnight with 1 M A1-42 and mitochondrial morphology recorded after labeling with MitoTracker (pseudocolored in red). Panels on
right side show details of panels on left side. Scale bars = 20 m (left) and 2 m (right). B–D: Morphometric analysis of mitochondria from
wild-type and nSMase2-deficient astrocytes with (A) or without [control (Con)] A treatment. Mitochondrial length [**P < 0.01 (B)], aspect
ratio [**P < 0.01 (C)], and form factor [***P < 0.001 (D)] were calculated using ImageJ (n = 3 independent cell cultures with five randomly
selected areas per culture). E, F: Mitochondrial motility. Fifteen frames (one frame per minute) of wild-type and nSMase2-deficient astrocytes
were recorded using time-lapse in vivo imaging. Mitochondria were labeled with CytoPainter (t0 pseudocolored in green, t1 pseudocolored in
red). Motility of perinuclear (N) and peripheral (P) mitochondria was quantified using colocalization analysis (ImageJ) in two consecutive
time frames (t0 and t1) (n = 3 independent cell cultures with five randomly selected areas per culture; **P < 0.01; scale bar = 50 m).

-tubulin, suggesting that potential interaction of ceramide
with tubulin is important for the regulation of mitochondrial function and motility.
Tubulin is cross-linked to pacFACer and binds to ceramide
Our earlier studies showed that tubulin was coimmunoprecipitated when pulling down intracellular vesicles using

the anti-ceramide antibody (20). However, whether tubulin interacts directly with ceramide and what the function
of this potential interaction is remained unclear. To test
this, we used a bifunctional ceramide analog (pacFACer)
that can be UV-cross-linked to ceramide binding proteins
and then derivatized by click chemistry with fluorophores
or biotin, a novel labeling technique recently developed
Ceramide-associated tubulin regulates mitochondria
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Fig. 2. Ceramide is colocalized with MAMs, peripheral mitochondria, and microtubules, which is prevented by nSMase2 deficiency and
FB1 treatment. A: Immunocytochemistry using MitoTracker (pseudocolored in blue) and antibodies against ceramide (rabbit IgG, pseudocolored in red) and SigmaR1 (goat IgG, pseudocolored in green). The left panel shows the overview with the inset frame at higher resolution
shown in the right panel. The middle panel shows the profile of fluorescence signal intensity along the dashed line in the right panel, indicating colabeling of ceramide and SigmaR1 at mitochondria (white color in image). The y-axis in the middle panel shows arbitrary units of fluorescence signal intensity. B: Colocalization of ceramide (pseudocolored in red) with MitoTracker (pseudocolored in green) in WT and
nSMase2-deficient astrocytes. The arrows point at peripheral mitochondria (n = 5 independent cultures; **P < 0.01). C: Colocalization of
ceramide (pseudocolored in red) and acetylated tubulin (pseudocolored in blue) in WT and nSMase2-deficient astrocytes. Mitochondria are
pseudocolored in green (n = 4 independent cultures; ***P < 0.001).
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Fig. 3. Ceramide forms contact structures with microtubules and codistributes with tubulin. A: Confocal
immunofluorescence microscopy using anti-ceramide
rabbit IgG (pseudocolored in red) and anti-acetylated
tubulin mouse IgG (pseudocolored in green). The image shows Z-scan projection onto one plane. Scale bar =
20 m. B: The image shows detail from A (frame) at
higher magnification. Scale bar = 2 m. C: NSTORM
using antibodies as described in A. Arrows point at potential contact structures (yellow) between ceramide
(CEMAM) and microtubules. Scale bar = 500 nm. D:
Confocal immunofluorescence microscopy using astrocytes labeled with MitoTracker (pseudocolored in
blue) and then subjected to immunocytochemistry
with anti--tubulin mouse IgG (pseudocolored in red)
and anti-ceramide rabbit IgG (pseudocolored in green).
The right panel shows fluorescence signal intensity
and distribution indicating colocalization of antigens
at mitochondria.

for sphingolipids (19, 66–68). In addition, we used ceramidelinked agarose beads to pull down and identify ceramide
binding proteins from cell lysates.
In a cell-free assay, lipid-adsorptive ELISA plates were
coated with pacFACer and then incubated with purified tubulin from pig brain. After UV cross-linking, unbound tubulin was washed out and the cross-linked protein tagged
with Cy7.5 and then eluted with SDS sample buffer. Figure
4A, B shows that only tubulin exposed to UV was labeled
(lanes 7 and 9, arrow), while the control (without UV) remained unlabeled (lanes 6 and 8). BSA was not significantly cross-linked to pacFACer (Fig. 4A, B, lanes 4 and 9),
although its concentration was more than 10-fold of that of
tubulin (1 mg/ml vs. 0.08 mg/ml). A proteomics analysis
of Cy7.5-labeled tubulin (Fig. 4A, B, lanes 7 and 9) led to
the identification of the tryptic peptide, M363AATFIGNSTAIQELFK379, in the -tubulin isoform tubb4a (UniProt
accession number F2Z5K5) as the candidate sequence
cross-linked to pacFACer.
A preliminary modeling analysis of potential ceramide
binding sites using the UCSF Zinc database (C16:0 ceramide, zinc_40164304.mol2), RCSB PDB database (
tubulin dimer, ijff.pdb), and Swissdocks program suggested three potential ceramide binding sites in the dimer
(supplemental Fig. S3C) with binding energies of more
than 8 kcal/mol (equivalent to an equilibrium constant
of <1 M). As a comparison, the intracellular tubulin

concentration can go up to about 1 mg/ml or 20 M,
which is slightly above the threshold for microtubule selfassembly (0.8 mg/ml) (69, 70). Site 1 was close to the maytansine and GTP binding sites in the vicinity of helices
H3-H3′ (71). Site 2 was similar to the taxol binding site
close to the M-loop region (72). Site 3 was in proximity to
the C-terminal helices H10-H11 and overlapped with the
peptide identified by proteomics analysis (supplemental
Fig. S3C, D). The molecular modeling analysis was consistent with the results from pacFACer cross-linking and may
therefore represent potential binding sites for ceramide in
- and -tubulin.
To confirm cross-linking to cellular tubulin, homogenized astrocytes were incubated with pacFACer and the
cross-linked protein tagged with biotin followed by streptavidin pull-down. Proteomics analysis and immunoblotting sug
gested that -tubulin (UniProt accession number P99024)
was pulled down from the cross-linked sample (Fig. 4C,
lane 3). Tubulin was not significantly cross-linked to other
photoactivatable lipids, including photoactivatable fatty
acid and sphingosine, demonstrating specificity of the reaction with pacFACer (67, 68, 73). In addition, we used
ceramide-linked agarose beads to test which tubulin isoforms from a cellular homogenate bind to ceramide (Fig.
4D, lane 2). Proteomics analysis of the eluate showed that
various -tubulin (P68369, P05213, P68373, and Q9JJZ2)
and -tubulin (P99024, P68372, Q7TMM9, Q9ERD7, and
Ceramide-associated tubulin regulates mitochondria
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Fig. 4. Cross-linking of pacFACer to tubulin and binding to ceramide. A, B: Tubulin from pig brain was cross-linked to pacFACer, tagged
with Cy7.5 azide, and then separated by SDS-gel electrophoresis [fluorescence scanning (A); Coomassie staining (B)]. Lane 1, control tubulin (1 g); lane 2, protein standard; lane 3, BSA  UV; lane 4, BSA + UV; lane 5, protein standard; 6, tubulin  UV; lane 7, tubulin + UV;
lane 8, tubulin + BSA  UV; lane 9, tubulin + BSA + UV. The arrow points at the tubulin band. C: Protein from astrocytes was cross-linked to
pacFACer, tagged with biotin azide, and the protein pulled down with streptavidin agarose beads. Immunoblot was performed using
-tubulin mouse IgG Lane 1, click reaction without pacFACer; lane 2, with pacFACer  UV; lane 3, with pacFACer + UV. D: Pull-down of
protein with control agarose (Con) or ceramide-linked agarose beads (Cer). The immunoblot of protein in the eluate was probed with
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Q922F4) isoforms were among the ceramide-binding proteins. Immunocytochemistry at higher resolution showed
that ceramide colabeled with contact structures between
microtubules and mitochondria (Fig. 4E, arrows), suggesting that ceramide is important for the function of
membranous contact sites between microtubules and
mitochondria.
pacFACer-cross-linked tubulin is translocated from
the perinuclear region to peripheral CEMAMs and
codistributes with ceramide
Based on the observation that pacFACer was cross-linked
to tubulin, we investigated to determine whether intracellular pacFACer label colocalized with ceramide and tubulin at CEMAMs, mitochondria, or microtubules. Initially,
we immediately fixed astrocytes after pacFACer incubation
and UV cross-linking (0 h post-cross-linking), a procedure
described for other bifunctional sphingolipid analogs with
only minimal metabolic turnover of ceramide into other
sphingolipid derivatives that may cross-link to proteins
(68). In contrast to these previous studies, we also introduced a post-cross-linking incubation step (24 h), allowing
intracellular trafficking of the pacFACer-linked protein.
pacFACer remaining in the cell, but not cross-linked and
further metabolized to other sphingolipid analogs (e.g.,
sphingomyelin), was washed out with methanol following
fixation. The pacFACer-linked protein was visualized using
click chemistry-mediated tagging with fluorophores.
Fixation immediately after cross-linking (0 h post-crosslinking) led to pacFACer labeling of a perinuclear compartment (Fig. 5A) that partially colocalized with calnexin,
a chaperone and calcium regulator found in the ER and
some ER-derived subcompartments, such as MAMs (Fig.
5C) (74). There was little or no distribution of pacFACer to
the cell periphery (area labeled P in Fig. 5C). The pacFACer-labeled compartment also partially colocalized with
GM130 (supplemental Fig. S3E), a golgin family protein
important for microtubule assembly and ER-to-Golgi trafficking (75), suggesting that initial cross-linking of pacFACer
to protein was limited to the perinuclear ER and/or Golgi.
Incubation for 24 h post-cross-linking led to the gradual
appearance of pacFACer labeling in the cell periphery
(Fig. 5B, D). Figure 5E shows imaging results obtained after ectopic expression of the GFP-tagged ER marker protein, Sec61 (Sec61-GFP), in HEK293T cells. Codistribution
of the pacFACer label with Sec61-GFP (solid arrows) and
MitoTracker (dashed arrows) was consistent with the results obtained with pacFACer cross-linking in astrocytes.
Next, we tested to determine whether pacFACer and ceramide were codistributed in the same compartment(s),
particularly microtubules, MAMs, and mitochondria. Figure 6A–C shows that pacFACer and ceramide were colabeled
with isoforms of tubulin along microtubules. Colabeling
was also detected in MAMs (arrows in Fig. 6D), suggesting

that pacFACer-cross-linked protein was transported to
CEMAMs to contact structures with microtubules and mitochondria. Figure 7A–E shows that pacFACer and ceramide were codistributed at peripheral mitochondria
(arrows in Fig. 7A) along microtubules (arrows in Fig. 7B).
Using higher resolution confocal microscopy (Fig. 7C) and
STORM (Fig. 7D), we found that codistribution of pacFACer
with ceramide was limited to contact structures (arrows in
Fig. 7D, right panel), consistent with the assumption that
pacFACer-cross-linked tubulin was localized in CECs, particularly CEMAMs that formed attachment sites with microtubules and mitochondria, as shown in Fig. 4E (arrows).
Similar to the effect of ceramide depletion on the distribution of CEMAMs (Fig. 2B), we tested to determine
whether nSMase2 deficiency reduced colabeling of pacFACer with mitochondria. While nSMase2 deficiency did
not significantly change codistribution of pacFACer with
mitochondria located closer to the nucleus (area of interest labeled N), there was a significant reduction of label at
peripheral mitochondria (area of interest labeled P) in
nSMase2-deficient astrocytes (Fig. 7E, F). Taken together,
these results suggested that after initial cross-linking in the
perinuclear ER (or Golgi), pacFACer-cross-linked tubulin
was distributed to CEMAMs and mitochondria, which was
prevented by ceramide depletion.
Ceramide depletion reduces association of ceramide with
tubulin at mitochondria
Our results were consistent with the assumption that
tubulin was cross-linked to pacFACer and transported to
CEMAMs. Therefore, we tested to determine whether ceramide was associated with tubulin at CEMAMs, and
whether CAT formation or distribution was reduced by
ceramide depletion in nSMase2-deficient or FB1-treated
astrocytes. Apart from cross-linking of pacFACer, there is
currently no assay able to visualize direct binding of ceramide to a particular protein in intact cells. Recently,
PLAs have been developed to detect formation of protein
or other complexes by immunocytochemistry. PLAs use
short cDNA strands attached to secondary antibodies to
amplify a fluorescence signal by rolling circle PCR if the
primary antibodies are in close vicinity (<40 nm), indicating
complex formation of the antigens (76, 77). To date, the
anti-ceramide IgG is the only ceramide-specific antibody
that can be used for PLA with commercially available secondary antibodies.
Figure 8A–D shows that PLA signals using anti-ceramide
[rabbit IgG (+) strand secondary antibody] and anti-tubulin [mouse IgG () strand secondary antibody] were
predominantly associated with cross-linked pacFACer and
MitoTracker labeling, suggesting that CAT complexes are
formed at contact structures of CEMAMs with mitochondria. Pairing nonspecific rabbit IgG or mouse IgG with
anti-rabbit IgG (+) and anti-mouse IgG () did not yield

anti-detyrosinated -tubulin rabbit IgG. E: High-resolution confocal microscopy showing arrangement of microtubules (MT), mitochondria
(Mito), and ceramide (middle and right panels show z-stack reconstruction along dashed line in the left panel). The arrows point at contact
structures of ceramide (CEMAM) with microtubules and mitochondria.
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Fig. 5. Protein cross-linked to pacFACer is transported from the perinuclear region to the cell periphery. A, B: Primary cultured astrocytes were incubated
with pacFACer and either immediately fixed after
cross-linking (A) or incubated for another 24 h prior
to fixation (B) and subjected to click chemistry-mediated labeling with Alexa647-azide (pseudocolored
in red) and immunocytochemistry using an antibody
against acetylated tubulin (mouse IgGs, pseudocolored in green). C, D: Experiment performed as in A
and B, and immunolabeled for calnexin (mouse IgG,
pseudocolored in green). N, perinuclear region; P,
cell periphery. Scale bars = 10 m. E: HEK293T cells
expressing the ER marker, Sec61-GFP (Secgfp) (pseudocolored in green), cross-linked with pacFACer (pac)
(pseudocolored in red, solid arrows), and labeled with
MitoTracker (Mito) (pseudocolored in blue, dashed
arrows). The left panel is an overview with framed area
shown at high resolution in the middle and right panels. Scale bars = 20 (left panel) and 2 m (middle and
right panels).

PLA signals demonstrating specificity of the method (not
shown). It should be noted that at higher resolution, the
dot-like PLA signal did not exactly codistribute with the antigens or site of antibody binding, but rather showed a
stalk-drop appearance (arrows in Fig. 8D) as the signal for
ceramide-tubulin interaction colocalized with pacFACerlabeled mitochondria (dashed arrows point at the initial
binding sites for the secondary antibodies). The number of
PLA signals was reduced in nSMase2-deficient astrocytes
and cells (astrocytes and HEK293T) treated with the CerS
inhibitor, FB1 (Fig. 8B, E, left panel, only HEK293T cells
are shown), consistent with decreased colocalization of ceramide and pacFACer at mitochondria. Figure 8F confirms
colocalization of the PLA signal for the CAT complex with
mitochondria (arrows).
Ceramide depletion reduces complex formation between
tubulin and VDAC1 and increases cellular ATP levels
The formation of CAT complexes and its reduction by
ceramide depletion implies that association with ceramide may regulate the function of tubulin at mitochondria.
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Previous studies showing that tubulin closes VDAC1 suggested that CAT may regulate VDAC1 (52, 54, 78). We
performed PLAs for CAT-dependent formation of VDAC1tubulin complexes using anti-VDAC1 [rabbit IgG (+)] and
anti-- or --tubulin [mouse IgG ()] antibodies with wildtype and nSMase2-deficient astrocytes. Figure 9A, B and
supplemental Fig. S4A, B show that nSMase2 deficiency
or FB1-mediated inhibition of CerSs led to 70% reduction
of the number of PLA signals for complex formation between VDAC1 and tubulin. Image analysis at higher resolution confirmed that the signals indicating VDAC1-tubulin
complexes were located at mitochondria (Fig. 9C, D, supplemental Fig. S4C), consistent with the localization of
CATs (Fig. 8D, F).
To confirm the validity of the PLA results, we performed
coimmunoprecipitation assays using anti--tubulin mouse
IgG for the immunoprecipitation and anti-VDAC1 rabbit
IgG for the immunoblotting reaction with HEK293T cells
with or without FB1 treatment. Figure 9E, F shows that in
HEK293T cells, the number of PLA signals for the VDAC1tubulin complex was reduced by ceramide depletion to the
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Fig. 6. Protein cross-linked to pacFACer colocalizes
with ceramide at microtubules and CEMAMs in the
cell periphery. A–C: Confocal immunofluorescence
microscopy (Z-scan projections) using primary astrocytes subjected to pacFACer cross-linking and tagging
with Alexa647 azide (24 h post-cross-linking, pseudocolored in blue) and antibodies against ceramide
(rabbit IgG, pseudocolored in green) and acetylated
tubulin [mouse IgG (A)], -tubulin [mouse IgG (B)],
-tubulin [mouse IgG (C)], or -tubulin tubb4/5
[mouse IgG (D)] all pseudocolored in red. Scale bars =
2 m. D: Same as in A–C, but using antibody against
SigmaR1 (goat IgG, pseudocolored in red). The arrows point at pacFACer-labeled CEMAMs.

same extent as with astrocytes (supplemental Fig. S4A, B).
For the coimmunoprecipitation experiment, digitonin
(1%) was used as a detergent because it is known to preserve the membrane environment in ceramide biosynthesis
and it is commonly used for solubilization of proteins from
the OMM (79–81). Figure 9G shows that ceramide depletion reduced the amount of coimmunoprecipitated
VDAC1 (nontreated cells and nonspecific mouse IgG were
used as controls) consistent with the decrease of the number of PLA signals for the VDAC1-tubulin complex in
HEK293 cells (Fig. 9E, F). The reverse immunoprecipitation reaction using anti-VDAC1 rabbit IgG and anti-tubulin for immunoblotting did not show a signal, possibly
due to inaccessibility of VDAC1 to its antibody in digitoninsolubilized membranes (not shown).
While tubulin-mediated closure of the VDAC1 channel
was shown to block ADP/ATP transport, the effect of this
regulation on the intracellular ATP concentration has not
been reported yet. There are numerous reports, however,
that VDAC1 downregulation profoundly decreases levels of
intra- and extracellular (secreted) ATP (45, 46, 82). Based
on our observation that ceramide depletion decreases
complex formation between tubulin and VDAC1, we tested
to determine whether reducing ceramide would upregulate cellular ATP levels. Figure 9H, I shows that ATP levels

of nSMase2-deficient or FB1-treated astrocytes were 40%
higher than those in wild-type controls. Increase of cellular
ATP by ceramide depletion was consistent with higher mitochondrial motility and resistance to A, although further
research is needed to understand these potentially related
effects. Notwithstanding this limitation, our research strongly
suggests that there is a novel function of ceramide for mitochondria regulating ATP levels, motility, and resistance to
A mitotoxicity.

DISCUSSION
For two decades, research on ceramide in mitochondria
was focused on its role in the induction of apoptosis. This
focus appeared justified because strong experimental
evidence supported the notion that ceramide generated by
SMase(s) at mitochondria induced apoptosis, probably by
forming channels for pro-apoptotic proteins in the OMM
(59, 61, 83–85). However, the abundance of ceramide in
MAMs under physiological conditions also suggested other
functions of ceramide that were only poorly understood.
Compartmentalization of ceramide in microdomains (rafts)
or more extended membrane areas and its physiological
function remained elusive. About 10 years ago, our laboratory developed a polyclonal ceramide antibody that proved
Ceramide-associated tubulin regulates mitochondria
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Fig. 7. Protein cross-linked to pacFACer colocalizes with ceramide at mitochondria in cell periphery, which is prevented in nSMase2-deficient
cells. A: Astrocytes subjected to pacFACer cross-linking and labeled with MitoTracker (24 h post-cross-linking, pseudodcolored in blue)
underwent click chemistry-mediated tagging with Alexa647 azide (pseudocolored in red) and immunocytochemistry using anti-ceramide
rabbit IgG (pseudocolored in green). The left panel shows an overview with panels on the right showing details of the framed area at high
resolution. The arrow in the left panel points at the perinuclear region with codistribution of pacFACer and ceramide. The arrows in
the panels on the right point at peripheral mitochondria colabeled for ceramide and pacFACer. B: pacFACer/Alexa647-tagged protein
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Fig. 8. Ceramide depletion reduces formation of
CAT complexes at mitochondria. A–D: PLAs indicating complex formation between ceramide and tubulin in astrocytes. Astrocytes subjected to pacFACer
cross-linking and labeled with MitoTracker (24 h
post-cross-linking, pseudocolored in red) underwent
click chemistry-mediated tagging with Alexa647
azide (pseudocolored in blue) and PLAs using anticeramide rabbit IgG (+) and anti -tubulin mouse IgG
() (PLA pseudocolored in green) in WT and nSMase2-deficient astrocytes. Images are shown at higher
magnification and association of PLA signals with pacFACer-labeled mitochondria (C, D). Stalk-drop appearance (solid arrow) of high resolution PLA signal
attached to mitochondrium (dashed arrow, initial attachment site of secondary antibodies) (D). E, F: PLA
using HEK293T cells, anti-ceramide rabbit IgG (+),
and anti--tubulin mouse IgG (). Signals for CAT
complexes are pseudocolored in green; MitoTracker is
pseudocolored in red. Scale bars = 20 m. F: Detail
with arrows pointing at PLA signal at mitochondria
(Z-scan in bottom panel). Scale bar = 2 m.

useful for visualizing ceramide in fixed cells and tissues using immunocytochemistry (24). It was shared with many
other laboratories to determine the intracellular distribution of ceramide and was instrumental to our research on
CECs (18–21, 25, 27). Most recently, this antibody allowed
the visualization of ceramide rafts using super-resolution
microscopy (dSTORM) (18), clearly demonstrating that
the distribution of ceramide in cellular membranes is
anisotropic and regulated by SMase(s).
In addition to anti-ceramide IgG, a new generation of
ceramide analogs was developed to use click chemistry-mediated addition of fluorophores after the analog inserted
into cellular membranes (66, 86). We and our collaborators showed that these analogs are codistributed with CECs

detected by the antibody (25). Using a modified version of
these analogs, bifunctional ceramide analogs (pacFACer)
that can be UV-cross-linked to ceramide binding proteins
and derivatized using click chemistry, we demonstrated
that pacFACer can be cross-linked to protein in CECs (19).
In the present study, we discovered that CEMAMs contain
protein cross-linked to pacFACer. While it is currently not
possible to clearly identify the cross-linked protein by immunocytochemistry, pull-down assays and PLAs suggest
that tubulin is a protein bound by ceramide in CEMAMs.
This assumption is supported by the observation that
ceramide depletion by nSMase2 deficiency or CerS inhibition with FB1 reduces the number of PLA signals at mitochondria when using anti-ceramide and tubulin antibodies.

(pseudocolored in red) is colocalized with peripheral mitochondria (Tom 20, pseudocolored in green) along microtubules (acetylated tubulin, pseudocolored in blue). C, D: Confocal immunofluorescence microscopy [Z-scan projection onto one plane (C)] and NSTORM super resolution fluorescence microscopy of pacFACer-cross-linked protein tagged with Alexa647 azide [pseudocolored in green (D)]
combined with anti-Tom 20 rabbit IgG (Atto488, pseudocolored in green). The panel on the left side in D shows an overview of the NSTORM
image; the panels on the right show details of the frame in the left panel. The arrows indicate colocalization at potential contact sites between
ceramide (CEMAMs) and mitochondria. Scale bar = 500 nm. E, F: Colocalization of pacFACer (pseudocolored in red) and MitoTracker
(pseudocolored in green) in WT and nSMase2-deficient astrocytes. The frames in the figure panels indicate perinuclear (N) and peripheral
(P) mitochondria, respectively (scale bar = 5 m; n = 5 independent cell cultures with five randomly selected areas per culture; **P < 0.01).
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Fig. 9. Ceramide depletion reduces VDAC1-tubulin complex formation at mitochondria and increases intracellular ATP levels. A–D: Astrocytes were labeled with MitoTracker (pseuodcolored in red) and PLAs performed using anti-VDAC1 rabbit IgG (+) and anti--tubulin
mouse IgG () (PLA pseudocolored in green). B: Quantitation of VDAC1-tubulin complexes in WT and nSMase2-deficient astrocytes
(n = 4 independent cell cultures; **P < 0.01). C: Detail from A (frame in left panel) and fluorescence signal intensity profile indicating association of PLA signals with mitochondria. D: Detail from C (frame). E, F: PLA using anti-VDAC1 rabbit IgG (+) and anti--tubulin mouse
IgG () with nontreated and FB1-treated HEK293T cells. Signals for VDAC1-tubulin complexes are pseudocolored in green, MitoTracker is
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Fig. 10. Hypothetical mechanism of VDAC1 closure by CAT in CEMAMs. A: Elevated cytosolic tubulin levels
due to increased microtubule disassembly/reduced assembly lead to association of tubulin with ceramide in
CEMAM-resident CATs that wrap around mitochondria and block VDAC1-mediated ADP/ATP transport between mitochondria and the cytosol. Lack of ATP leads to inactivation of motor proteins and mitochondria
stop moving (STOP mode). B: When microtubules extend to the periphery, cytosolic (free) tubulin concentration is low, VDAC1 unblocked, and ATP available to drive mitochondria transport along microtubules (GO
mode). Higher ceramide levels facilitate ATP deprivation and the STOP mode, while low ceramide levels favor ATP release and the GO mode. This leads to higher mitochondrial motility in nSMase2-deficient or FB1treated astrocytes. C, D: Potential arrangement and ceramide binding of  tubulin dimers interacting with
VDAC1 in the OMM. Note that binding of -tubulin to ceramide in CATs is likely to be mediated by protein
domains defined as cluster 2 from molecular modeling shown in supplemental Fig. S3C, D. Also note that
complex formation with VDAC1 is likely to be mediated by the dimer with -tubulin reaching into the VDAC1
pore with its C-terminal tail (CTT).

It should be noted, however, that any PLA signal is evidence for, but not absolute proof of, a complex because its
components can still be about 40 nm apart.
Despite this caveat, there is solid evidence from independent studies that ceramide binds directly to tubulin
(20, 28, 29). Molecular modeling predicts that the affinity
of tubulin for ceramide is relatively low (0.5–1 M), which
may turn CAT into a sensor for free tubulin at physiological levels in the cytosol to block VDAC1 and ATP release,
provided that sufficient ceramide for CAT formation is
available (Fig. 10A). On the other hand, if ceramide levels
are low, formation of CAT is also reduced and ATP release
and mitochondrial motility increased (Fig. 10B). Our
model predicts that CEMAMs engage CAT into blocking
VDAC1 in a zipper or Velcro-like way (Fig. 10C): simultaneous CAT formation in several complexes with VDAC1
will stabilize the contact of CEMAMs to the OMM despite
presumably lower affinity for the individual ceramide-tubulin interaction. This interaction is likely to be mediated
by a tubulin dimer with -tubulin binding to ceramide and
the C-terminal tail of (detyrosinated) -tubulin reaching
into the VDAC1 channel (Fig. 10D).
Previous studies using a similar or the same ATP assay as
applied in our study showed that VDAC1 downregulation
leads to reduced levels of intracellular ATP (45, 46, 82). This
observation is quite remarkable because this assay does not

distinguish between mitochondrial or cytosolic ATP levels,
indicating that blocking VDAC1 will reduce both ATP pools.
It should be noted, however, that the results of the ATP assay
do not exclude the effect of ceramide on other ATP regulatory mechanisms, such as aerobic glycolysis or the activity of
the adenine (ADP/ATP) nucleotide translocator (ANT), an
ADP/ATP exchanger located in the inner mitochondrial
membrane (87). The interaction of ANT with CerS6 has
been reported to be involved in ceramide-induced prevention of permeability transition pore opening and calcium accumulation in mitochondria of oligodendrocytes (62). It
remains to be determined whether the interaction of ceramide-enriched membrane domains with transporters and
channels in the inner mitochondrial membrane, OMM, or
MAM is part of a regulatory cascade or module to affect energy and calcium homeostasis in mitochondria.
There is some discrepancy in which VDAC isoform is
more critical for regulation of intracellular ATP, which is
likely to be cell-type specific (51, 52). Most recently, excess
elevation of ceramide has been shown to induce mitophagy,
suggesting that the physiological function of ceramide, as
discussed in our study, requires limitation of its concentration at mitochondria (88, 89). While ATP levels observed in
our study are consistent with CAT-regulated ATP release
under normal physiological conditions, several studies have
shown that, under pathophysiological conditions, reduction

pseudocolored in red (scale bars = 20 m; n = 4; *P < 0.05). G: Coimmunoprecipitation analysis of the VDAC1-tubulin complex in control
(Con) and ceramide-depleted (FB1-treated) HEK293T cells. Input is protein after solubilization of mitochondria with 1% digitonin used for
incubation with anti--tubulin mouse IgG or nonspecific mouse IgG (control). Output is protein eluted after pull-down with anti-mouse IgG
gel beads and immunoblotted using anti-VDAC1 rabbit IgG. Ceramide depletion was achieved by incubation of cells for 60 h with 3 M FB1.
Lane 1, input control cells; lane 2, input FB1-treated cells; lane 3, output control IgG with nontreated cells; lane 4, output anti--tubulin IgG
with nontreated cells; lane 5, output control IgG with FB1-treated cells; lane 6, output anti--tubulin IgG with FB1-treated cells. H, I: ATP
levels in WT (H) or control (Con) (I) and nSMase2-deficient (H) or FB1-treated (I) astrocytes (n = 4 independent cell cultures; *P < 0.05;
**P < 0.01).
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of ATP levels are concurrent with decreased mitochondrial
motility and increased fragmentation (44, 90–92). The contribution of excess ceramide to this mitotoxicity is likely to
include additional mechanisms, which will be explored in
future studies. Likewise, there is discrepancy in the literature with respect to the effect of FB1 on mitochondria. FB1
has been shown to protect cells from apoptosis by reducing
the effect of ceramide on mitochondria, but it has also been
described to inhibit mitochondrial complex I and induce
cell death (93–95). This discrepancy may be due to different FB1 concentrations and incubation times, as well as the
limitation that, in many of the previous studies, the effect of
FB1 was not compared with any other effects of ceramide
depletion by enzyme inhibition or deficiency in ceramide
metabolism. In our study, the results from the effect of FB1
are consistent with those from nSMase2 deficiency, supporting the conclusion that reduction of ceramide generation
leads to increase of ATP levels and, potentially, other beneficial effects, such as resistance to mitotoxic insults.
While reduction of ceramide levels is likely to be protective to mitochondria, excess ceramide elevation is common
to several neurodegenerative diseases. We and others have
shown that A activates nSMase2 and increases ceramide
levels in astrocytes and other neural cells (3, 4, 96–99). It is
reasonable to assume that mitotoxicity of ceramide involves
a cascade of cooperating mechanisms depending on its con
centration and distribution. Therefore, inhibiting ceramide
biosynthesis or downregulating nSMase2 may protect mitochondria from A-induced damage, although definition of
the exact mechanism will still require additional research.
One should also keep in mind that our experiments were
performed with cells in vitro. Any in vitro model can only
approximate the in vivo process and is subject to experimental limitations, particularly when attempting to emulate the conditions in the aging human brain. Despite this
limitation, preventing ceramide elevation emerges as
a promising strategy for therapy of AD and other neurodegenerative diseases and our results will help define a
common function of ceramide in the regulation and dysregulation of mitochondria in normal and pathological
brain, respectively.
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